Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Nexvax-2 vaccine is safe and bioactive in phase I trial in celiac disease

May 27, 2011

Findings disclosed from two phase II trials of NXL-104/ceftazidime

May 27, 2011

Preclinical data support further development of PF-4348235 for treatment of COPD

May 27, 2011

LIPN gene mutation correlates with late-onset autosomal recessive ichthyosis

May 27, 2011

Monoclonal antibody against beta-amyloid reduces symptoms of AMD in vivo

May 26, 2011

New selective glucocorticoid receptor antagonists prevent olanzapine-induced weight gain in vivo

May 26, 2011

MGMTP140K gene-modified cells are safe and confer chemoprotection in phase I/II glioblastoma trial

May 26, 2011

New vaccine targeting morphine dependency shows promise in rats

May 26, 2011

Ongoing phase I/II trial suggests safety of CDCA1-A24-56 vaccine in patients with CRPC

May 26, 2011

Mutations in CACNA2D1 gene may confer susceptibility to Brugada syndrome

May 25, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...